Weak fiscal Q1 due on 9 Feb. FX and Kerecis to disrupt Q1, but no change to guidance. SELL on valuation and lack of share price drivers in H1.

20 Dec 2023
Weak Q1e, hints of light at end of the tunnel

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Weak Q1e, hints of light at end of the tunnel
- Published:
20 Dec 2023 -
Author:
ABGSC Healthcare Research | Morten Larsen -
Pages:
13 -
Weak fiscal Q1 due on 9 Feb. FX and Kerecis to disrupt Q1, but no change to guidance. SELL on valuation and lack of share price drivers in H1.